146 related articles for article (PubMed ID: 17400992)
1. Food and Drug Administration public hearing of the conduct of emergency clinical research: testimony of Dr. Dutton.
Dutton RP
Acad Emerg Med; 2007 Apr; 14(4):e33-6. PubMed ID: 17400992
[No Abstract] [Full Text] [Related]
2. Food and Drug Administration public hearing on the conduct of emergency clinical research: testimony of Dr. Nelson.
Nelson RM
Acad Emerg Med; 2007 Apr; 14(4):e43-4. PubMed ID: 17322567
[No Abstract] [Full Text] [Related]
3. Food and Drug Administration public hearing on the conduct of emergency clinical research: testimony of Dr. Schmidt.
Schmidt TA
Acad Emerg Med; 2007 Apr; 14(4):e59-62. PubMed ID: 17331913
[No Abstract] [Full Text] [Related]
4. Food and Drug Administration public hearing on the conduct of emergency clinical research: testimony of Dr. Weisfeldt.
Weisfeldt ML
Acad Emerg Med; 2007 Apr; 14(4):e69. PubMed ID: 17331914
[No Abstract] [Full Text] [Related]
5. Food and Drug Administration public hearing on the conduct of emergency clinical research: testimony of Pediatric Emergency Care Applied Research Network.
Chamberlain JM; Singh T; Baren JM; Maio RF;
Acad Emerg Med; 2007 Apr; 14(4):e41-2. PubMed ID: 17322568
[No Abstract] [Full Text] [Related]
6. Food and Drug Administration public hearing on the conduct of emergency clinical research: testimony of the American Stroke Association.
Saver JL;
Acad Emerg Med; 2007 Apr; 14(4):e57-8. PubMed ID: 17322569
[No Abstract] [Full Text] [Related]
7. Food and Drug Administration public hearing on the conduct of emergency clinical research: testimony of the American College of Emergency Physicians.
Cairns CB;
Acad Emerg Med; 2007 Apr; 14(4):e31-2. PubMed ID: 17331911
[No Abstract] [Full Text] [Related]
8. Food and Drug Administration public hearing on the draft guidance for exception from informed consent requirements for emergency research: testimony of Novo Nordisk.
Weiskopf RB;
Acad Emerg Med; 2007 Apr; 14(4):e71-3. PubMed ID: 17322571
[No Abstract] [Full Text] [Related]
9. Recommendations for implementation of community consultation and public disclosure under the Food and Drug Administration "exception from informed consent requirements for emergency research": testimony of the American Heart Association.
Halperin H;
Acad Emerg Med; 2007 Apr; 14(4):e37-9. PubMed ID: 17400993
[No Abstract] [Full Text] [Related]
10. Food and Drug Administration public hearing on the conduct of emergency clinical research: testimony of the Society for Academic Emergency Medicine.
Biros MH;
Acad Emerg Med; 2007 Apr; 14(4):e27-9. PubMed ID: 17322570
[No Abstract] [Full Text] [Related]
11. Food and Drug Administration public hearing on the conduct of emergency clinical research: testimony of Dr. Pepe--defending the rights of all individuals to have access to potential life-saving therapies and resuscitation studies.
Pepe PE
Acad Emerg Med; 2007 Apr; 14(4):e51-6. PubMed ID: 17341677
[No Abstract] [Full Text] [Related]
12. Struggling with the rule: the exception from informed consent in resuscitation research.
Biros M
Acad Emerg Med; 2007 Apr; 14(4):344-5. PubMed ID: 17400997
[No Abstract] [Full Text] [Related]
13. Recommendations for implementation of community consultation and public disclosure under the Food and Drug Administration's "Exception from informed consent requirements for emergency research": a special report from the American Heart Association Emergency Cardiovascular Care Committee and Council on Cardiopulmonary, Perioperative and Critical Care: endorsed by the American College of Emergency Physicians and the Society for Academic Emergency Medicine.
Halperin H; Paradis N; Mosesso V; Nichol G; Sayre M; Ornato JP; Gerardi M; Nadkarni VM; Berg R; Becker L; Siegler M; Collins M; Cairns CB; Biros MH; Vanden Hoek T; Peberdy MA; ;
Circulation; 2007 Oct; 116(16):1855-63. PubMed ID: 17893277
[No Abstract] [Full Text] [Related]
14. Response to Food and Drug Administration draft guidance statement on research into the treatment of life-threatening emergency conditions using exception from informed consent: testimony of the Resuscitation Outcomes Consortium.
Ornato JP
Acad Emerg Med; 2007 Apr; 14(4):e45-9. PubMed ID: 17400994
[No Abstract] [Full Text] [Related]
15. Effect of the final rule on the conduct of emergency clinical research.
Gonzalez SK; Helling TS
J Trauma; 2008 Jun; 64(6):1665-72. PubMed ID: 18545136
[TBL] [Abstract][Full Text] [Related]
16. The research on community consultation: an annotated bibliography.
Baren JM; Biros MH
Acad Emerg Med; 2007 Apr; 14(4):346-52. PubMed ID: 17400998
[TBL] [Abstract][Full Text] [Related]
17. Response to Food and Drug Administration draft guidance statement on research into the treatment of life-threatening emergency conditions using exception from informed consent: testimony of the neurological emergencies treatment trials.
Silbergleit R;
Acad Emerg Med; 2007 Apr; 14(4):e63-8. PubMed ID: 17331912
[No Abstract] [Full Text] [Related]
18. Toward ethical best practices in community consultation for research conducted with waiver of informed consent.
McCullough LB
Crit Care Med; 2008 Mar; 36(3):993-4. PubMed ID: 18431295
[No Abstract] [Full Text] [Related]
19. Waiver of informed consent for emergency research and community disclosures and consultations.
Raju TN
J Investig Med; 2004 Mar; 52(2):109-12. PubMed ID: 15068226
[No Abstract] [Full Text] [Related]
20. A study of warning letters issued to clinical investigators by the United States Food and Drug Administration.
Bramstedt KA
Clin Invest Med; 2004 Jun; 27(3):129-34. PubMed ID: 15305804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
